Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeradigmMDRX +1.87%23 EV-to-EBITDA is -6.18 as of Aug. 28, 2026. GuruFocus rates MDRX with a GF Score™ of 23/100. Among 517 Healthcare Providers & Services companies, Veradigm ranks worse than 193423.4% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Veradigm's enterprise value is $466.7 Mil.
Veradigm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 was $-75.5 Mil. Therefore, Veradigm's EV-to-EBITDA for today is -6.18.
The historical rank and industry rank for Veradigm's EV-to-EBITDA or its related term are showing as below:
MDRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.3 Med: 0 Max: 0
Current: -6.18
MDRX's EV-to-EBITDA is ranked worse than 100% of 517
companies
in the Healthcare Providers & Services industry
Industry Median: 10.49
vs MDRX: -6.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Veradigm's share price for today is $4.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Veradigm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-2.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Veradigm's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Veradigm's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veradigm EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veradigm's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Veradigm's EV-to-EBITDA falls into.
Veradigm's current Enterprise Value is $466.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Veradigm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 was $-75.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veradigm (MDRX) has a EV-to-EBITDA of -6.18 as of Aug. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Veradigm. According to the industry distribution chart, Veradigm ranks #999999 out of 517 companies in the Healthcare Providers & Services industry.
Is Veradigm's EV-to-EBITDA too high?
Veradigm's current EV-to-EBITDA is -6.18. Based on the distribution chart, Veradigm ranks #999999 out of 517 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Veradigm has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's EV-to-EBITDA compare to WEAV and PHR?
According to the Healthcare Providers & Services industry distribution chart, Veradigm ranks #999999 out of 517 companies for EV-to-EBITDA. This places Veradigm in the lower half of its industry. The industry median EV-to-EBITDA is 10.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.49, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Veradigm. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veradigm's current EV-to-EBITDA is -6.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (MDRX) has a current EV-to-EBITDA of -6.18. The current EV-to-EBITDA is -6.18. Veradigm's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Veradigm (MDRX), the current EV-to-EBITDA is -6.18 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
23GF Score
Get the complete analysis for MDRX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDRX has been successfully added to your 
